{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-183449","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.438006+00:00","generated_at":"2026-05-17T11:28:09.235650+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer","bullets":["All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.","Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.","FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).","Company plans to seek license partnerships for orphan indications to generate non-dilutive funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-183449","json":"https://secwatch.observer/filing/0001193125-25-183449.json","markdown":"https://secwatch.observer/filing/0001193125-25-183449.md","text":"https://secwatch.observer/filing/0001193125-25-183449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/0001193125-25-183449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/d947561d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:28:09.235650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}